(function(){var loadHandler=window['sl_{72C0429F-FC8A-44E7-B152-D6826999A52C}'];loadHandler&&loadHandler(123, '<div id="spr0_42c1b5d2"><div id="spr1_42c1b5d2" class="kern slide"><img id="img0_42c1b5d2" src="data/img2.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_42c1b5d2" class="kern slide"><div id="spr3_42c1b5d2" style="top:3.651px;"><div style="width:0px;"><span id="txt0_42c1b5d2" data-width="91.617188" style="left:211.413px;top:-0.954px;">Task 1</span></div></div><div id="spr4_42c1b5d2" style="left:30.545px;top:80.466px;"><div style="width:0px;"><span id="txt1_42c1b5d2" data-width="628.769531" style="left:7.2px;top:1.323px;">A patient has been referred to the breast cancer clinic with suspicion on breast cancer</span></div><div style="width:0px;"><span id="txt2_42c1b5d2" data-width="623.926758" style="left:7.2px;top:22.923px;">detected on mammography screening.  In the upper outer quadrant of the left breast</span></div><div style="width:0px;"><span id="txt3_42c1b5d2" data-width="607.491211" style="left:7.2px;top:44.523px;">there is a tumour ~1 cm in diameter.  Ultrasound-guided  tumour biopsy confirmed</span></div><div style="width:0px;"><span id="txt4_42c1b5d2" data-width="654.187500" style="left:7.2px;top:66.123px;">invasive ductal carcinoma.  Molecular markers: Estrogen receptor positive, HER2 positive.</span></div><div style="width:0px;"><span id="txt5_42c1b5d2" data-width="631.248047" style="left:7.2px;top:87.723px;">Patient is 45 years old.  The menses are regular. No signs of lymph nodes involvement.</span></div><div style="width:0px;"><span id="txt6_42c1b5d2" data-width="643.236328" style="left:7.2px;top:109.323px;">No signs of distant spread in liver (liver function tests and ultrasound) and lung (chest X-</span></div><div style="width:0px;"><span id="txt7_42c1b5d2" data-width="239.519531" style="left:7.2px;top:130.923px;">ray). No concomitant conditions.</span></div><div style="width:0px;"><span id="txt8_42c1b5d2" data-width="625.086914" style="left:7.2px;top:174.123px;">Present case summary to the class.  Compare the treatments below; suggest which of</span></div><div style="width:0px;"><span id="txt9_42c1b5d2" data-width="329.273438" style="left:7.2px;top:195.723px;">them may be suitable and which is not, why?</span></div><div style="width:0px;"><span id="txt10_42c1b5d2" data-width="618.046875" style="left:7.2px;top:238.923px;">1. Immediate tumour removal by conservative surgery (lumpectomy).  After surgery:</span></div><div style="width:0px;"><span id="txt11_42c1b5d2" data-width="395.208984" style="left:7.2px;top:260.523px;">adjuvant Tamoxifen for 5 years + Herceptin for 1 year.</span></div><div style="width:0px;"><span id="txt12_42c1b5d2" data-width="552.999023" style="left:7.2px;top:294.123px;">2. Mastectomy followed by radiotherapy and a course of adjuvant cytotoxic</span></div><div style="width:0px;"><span id="txt13_42c1b5d2" data-width="406.608398" style="left:7.2px;top:315.723px;">chemotherapy; Then Tamoxifen + Goserelin for 5 years.</span></div><div style="width:0px;"><span id="txt14_42c1b5d2" data-width="588.208008" style="left:7.2px;top:349.323px;">3. Neo-adjuvant Letrozole for 3 months followed by conservative surgery (sector</span></div><div style="width:0px;"><span id="txt15_42c1b5d2" data-width="570.682617" style="left:7.2px;top:370.923px;">resection).  After surgery: 5 years of adjuvant Letrozole + Herceptin for 1 year.</span></div><div style="width:0px;"><span id="txt16_42c1b5d2" data-width="482.422852" style="left:7.2px;top:404.523px;">Suggest what might be missed in the assessment and treatments?</span></div></div></div></div>');})();